Stathmin 1 expression in neuroendocrine and proliferating prostate cancer
Abstract Prostate cancer (PCa) is the second leading cause of cancer-related mortality among men in the United States. While PCa initially responds to androgen deprivation therapy, a significant portion progresses to castration-resistant PCa. Approximately 20–25% of these cases acquire aggressive ne...
Saved in:
Main Authors: | Yingli Shi, Yunshin A. Yeh, Siyuan Cheng, Xin Gu, Shu Yang, Lin Li, Nazih P. Khater, Susan Kasper, Xiuping Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2025-01-01
|
Series: | Discover Oncology |
Online Access: | https://doi.org/10.1007/s12672-025-01754-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Distribution of Neuroendocrine Cells in the Transition Zone of the Prostate
by: Yuki Kyoda, et al.
Published: (2017-01-01) -
Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma
by: Nicole M. Naranjo, et al.
Published: (2024-12-01) -
Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer
by: Zoe R. Maylin, et al.
Published: (2024-12-01) -
Leptin Regulates Proliferation and Apoptosis in Human Prostate
by: Eduardo Leze, et al.
Published: (2012-01-01) -
Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review
by: Xin Fei, et al.
Published: (2024-12-01)